Director, Graduate Medical Education & Designated Institutional Official, Children's Hospital Los Angeles
Director, Retinoblastoma Program
Attending Physician; Hematology, Oncology and Blood and Marrow Transplantation
Professor of Clinical Pediatrics (Educational Scholar)
  • Summary
  • Publications
  • Research
  • Locations

Rima  Jubran, MD, MPH, MACM is the Designated Institutional Official and Director of Graduate Medical Education at Children’s Hospital Los Angeles. In this role she oversees all the physician training programs at CHLA. In addition she is the medical director of the Retinoblastoma Program in the Children's Center for Cancer and Blood Diseases. Her clinical and research areas of focus are patients with retinoblastoma, neuroblastoma and the histiocytic diseases of childhood. She received her medical degree from Case Western Reserve University School of Medicine, Cleveland, Ohio, Master in Public Health degree at George Washington University, Washington, D.C and Master in Academic Medicine at the University of Southern California. Following her residency at Rainbow Babies and Children's Hospital in Cleveland, she completed a fellowship in pediatric hematology/oncology at Children's National Medical Center, Washington, D.C. Dr. Jubran is a member of the Retinoblastoma committee of the national Children's Oncology Group and the Steering committee on Langerhan’s Cell Histiocytosis of the Histiocyte Society. She is the principle investigator on multiple clinical trials targeting these diseases. Dr. Jubran serves on many committees at CHLA and USC including the Keck Faculty Council and Academic Senate. Most recently she was asked to participate on the Task Force on Workplace Standards and Employee Wellness. Dr. Jubran enjoys teaching and mentoring students,  physicians in training and junior faculty.. She has received multiple teaching and mentoring awards including the USC Mentoring Award for Faculty Mentoring Faculty and Graduate Students, the Walter Laug Award for Teaching and Mentorship (awarded by the Pediatric hematology/oncology fellows at CHLA) and the Outstanding Teaching in Professionalism in the Practice of Medicine award (awarded by the Keck medical students).

Clinical Interests

Areas of interest include retinoblastoma, neuroblastoma and histiocytic disorders of childhood.

Education

Medical School: 

Case Western Reserve University School of Medicine

Graduate School: 

George Washington School of Public Health - Masters in Public Health

University of Southern California - Masters in Academic Medicine

Internship: 

Rainbow Babies and Children's Hospital, Cleveland, OH

Residency: 

Rainbow Babies and Children's Hospital, Cleveland, OH

Fellowship: 

Children's National Medical Center, Washington, D.C. - Pediatric Hematology/Oncology

Accomplishments

Certification: 

Pediatric Hematology-Oncology: American Board of Pediatrics

Pediatrics: American Board of Pediatrics

Professional Memberships: 

American Society of Pediatric Hematology/Oncology; Children's Oncology Group; Histiocyte Society; AAMC-Group on Resident Affairs; Society for Pediatric Research

Awards: 

USC Mentoring Award for Faculty Mentoring Faculty and Graduate Students, 2017

Outstanding Teaching and Professionalism in the practic of medicine, Keck School of Medicine, 2012, 2015

Recipient of the Walter Laug Distinguished Teaching Award by the Pediatric Hematology/Oncology Fellows at CHLA

Best Doctors in America 2008-2014

Southern California Super Doctor 2012-2017

Other Information

Publications: 

* Indicates Trainees

** Indicates co-first or co-corresponding or senior authors

Jubran RF, Dinndorf PA. Successful therapy of refractory Graft Versus Host Disease with tacrolimus and PUVA. Therapeutic Drug Monitoring,20:236-239,1998.

Handa A, Jubran RF, Dickstein B, Boylan A, Luban NLC, Young  NS, Brown KE, GB virus C/Hepatitis G infection is frequent in American children and young adults. Clin Infect Dis. 30:569-571,2000.

Luban NL, Jubran RF. The transfusion-transmitted viruses in blood transfusion. Adv Exp Med Biol.489:1-12,2001.

Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG. Approaches to treatment for extraocular retinoblastoma: Childrens Hospital Los Angeles experience. J Pediatr Hematol Oncol. 26(1):31-4, 2004.

Chen ML*, Witmans MB, Tablizo MA, Jubran RF, Turkel SB, Tavare CJ, Keens TG. Disordered respiratory control in children with partial cerebellar resections. Pediatr Pulmonol. 40(1):88-91,2005.

Jubran RF, Marachelian A*, Dorey F, Malogolowkin, M. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer,45(1):37-42, 2005.

Sano H, Gonzalez-Gomez I, Wu SQ, Armenian SH*, Jubran RF, Shimada H. A Case of composite neuroblastoma composed of histologicaly and biologically distinct clones. Pediatric and Developmental Pathology, 10:229-232, 2007.

Fangusaro JR*, Jubran RF, Allen J, Gardner S, Dunkel IJ, Rosenblum M, Atlas M, Gonzalez I, Miller D, Finlay JL.  Brainstem Primitive Neuroectodermal Tumors (bstPNET): Results of Treatment with Intensive Induction Chemotherapy Followed by Consolidative Chemotherapy with Autologous Hematopoietic Cell Rescue. Pediatr Blood Cancer 50:715-717, 2008.

Armenian SH*, Panigrahy A, Murphree AL, Jubran RF. Management of retinoblastoma with proximal optic nerve enhancement on MRI at diagnosis. Pediatr Blood Cancer,51: 479-484, 2008.

Butturini AM, Jacob M, Aguajo J, Vander-Walde NA, Villablanca J, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Finlay JL. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome. Cancer,115(13):2956-63, 2009.

Dunkel IJ, Jubran RF, Gururangan S, Chantada GL, Finlay JL, Goldman S, Khakoo Y, O'Brien JM, Orjuela M, Rodriguez-Galindo C, Souweidane MM, Abramson DH. Trilateral Retinoblastoma: Potentially curable with intensive chemotherapy. Pediatr Blood and Cancer 54(3):384-7, 2010.

Khatua S*, Dhall G, O’Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL, Treatment of Primary CNS Germinomatous Germ Cell Tumors with Chemotherapy Prior to Reduced Dose Whole Ventricular and Local Boost Irradiation. Pediatr Blood Cancer 55(1):42-6,2010

Dunkel IJ, Chan HS, Jubran R, Chantada GL, Goldman S, Chintagumpala M, Khakoo Y, Abramson DH. High dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 55(1):149-52,2010

Bunin GR, Felice MA, Davidson W, Friedman DL, Shields CL, Maidment A, O’Shea M, Nichols KE, Leahey A, Dunkel IJ, Jubran R, Rodriguez-Galindo C, Schmidt ML, Weinstein JL, Goldman S, Abramson DH, Wilson MW, Gallies BL, Chan HS; Shapiro M, Cnaan A, Ganguly A, Meadows AT. Medical radiation exposure and risk of retinoblastoma resulting from a new germline RB1 mutation. Int J Cancer 128(10):2393-404, 2011.

Dhall G, Traverso M*, Finlay JL, Shane L, Gonzalez-Gomez I, Jubran R. The role of chemotherapy in pediatric clival chordomas. J Neurooncol,103(3);657-62,2011.

Parekh C*, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G. Treatment of children with recurrent high grade gliomas with bevacizumab containing regimen. J Neurooncol,103 (3):763-80,2011.  

Venkatramani R, Rosenberg S*, Indramohan G, Jeng M, Jubran R. An exploratory epidemiological study of Langerhans cell histiocytosis. Pediatr Blood Cancer.59(7):1324-6, 2012.

Gozali AE, Britt B, Shane L, Gonzalez I, Gilles F, McComb JG, Krieger MD, Lavey RS, Shlien A, Villablanca JG, Erdreich-Epstein A, Dhall G, Jubran R, Tabori U, Malkin D, Finlay JL. Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer, 58(6):905-9,2012.

Beckwitt Turkel S, Krieger MD, O'Neil S, Jubran R, Tavaré CJ. Symptoms before and after posterior fossa surgery in pediatric patients. Pediatr Neurosurg, 48(1):21-5,2012.

Julie G. Nyquist, Rima Jubran. How Learning Works: Seven Research-Based Principles for Smart Teaching. J Chiropr Educ, 26(2): 192–193,2012.

Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer, 60(2):175-84,2013.

Berry JL*, Jubran R, Kim JW, Wong K, Babayegy SR, Almarzouki H, Lee TC, Murphree AL. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer,60(4):688-93,2013.

Kotecha R*, Venkatramani R, Jubran RF, Arkader A, Olch AJ, Wong K. Clinical Outcomes of Radiation Therapy in the Management of Langerhans Cell Histiocytosis. Am J Clin Oncol. 37(6):592-6,2013

Lindsay H*, Jubran RF, Wang L, Kipp BR, May WA. Simultaneous colonic adenocarcinoma and medulloblastoma in a 12 year old with Biallelic deletions in PMS2. J. Pediatr, 163(2):601-3,2013

Berry JL, Jubran R, Wong K, Lee TC, Murphree AL Kim JW. Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low dose IMRT salvage: The Children’s Hospital Los Angeles Experience. Br J Ophthalmol, 98:1061-1065,2014.

Kamath S*, Arkader A, Jubran RF. Outcomes of children younger than 24 months with Langerhans cell histiocytosis and bone involvement: A report from a single institution. J Pediatr Orthop,34(8):825-30,2014.

Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma. Pediatr Hematol Oncol, 32:26-31,2015.

Chellapandian D, Shaikh F, van den Bos C, Somers GR, Astigarraga I, Jubran R, Degar B, Carret AS, Mandel K, Belletrutti M, Dix D, Visser J, Abuhadra N, Chang T, Rollins B, Whitlock J, Weitzman S, Abla O. Management and outcome of patients with Langerhans cell histiocytosis and single-bone CNS-risk lesions: A multi-institutional retrospective study. Pediatr Blood Cancer,62:2162-6,2015.

Berry JL, Jubran R, Murphree LM, Lee TC, Lee DK, Kim JW. Low-Dose Chemoreduction for infants diagnosed with retinoblastoma under 6 months of age. Ocul Oncol Pathol,1:103-110,2015.

Berry JL , Shih G , Moysidis SN , Jubran R , Wong K,  Lee TC, Murphree AL, Kim JW. Patterns of subretinal fluid resolution in Group D eyes treated with chemoreduction: Experience from the Children’s Hospital Los Angeles/University of Southern California. Ophthalmic Genetics 37:400-403,2016.

Zhu D*, Berry J, L, Ediriwickrema L, Wong K, Lee T, C, Murphree A, L, Kim J, W, Jubran R. Long-Term Outcomes of Group B Eyes in Patients with Retinoblastoma Treated with Short-Course Chemoreduction: Experience from Children's Hospital Los Angeles/University of Southern California. Ocul Oncol Pathol,2:105-111,2016.

Jacobsen BH*, Berry JL, Jubran R, Kim JW. Orbital recurrence following aggressive laser treatment for recurrent retinoblastoma. Ocul Oncol Pathol,2:76-79,2016.

Zweidler-McKay PA, Hogan MJ, Jubran R, Black V, Casillas J, Harper J. Malempati S. Margolin J, Felgenhauer J, Sakamoto KM, Franklin J, Shah M, Siebel N, Buchanan G, Vaiselbuh SR, Hastings C, Hildern J, Stork LC. Navigating your career path in pediatric hematology/oncology: On and off the beaten track. Pediatric Blood Cancer,63:1723-30,2016.

Friedman DL, Krailo M, Villaluna D, Gombos D, Lanholz B, Jubran R, Shields C, Murphree L, O’Brien J, Kessel S, Rodriguez-Galindo C, Chintagumpala M, Meadows AT. Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARTE0331): A report from the Children’s Oncology Group. Pediatr Blood Cancer 2017 Jul;64(7)doi 10.1002/pbc.26394 .

Kesselheim JC, Agrawal A, Bhatia N, Cronin A, Jubran R, Kent P, Kersun L, Rose M, Saveli S, Sharma M, Shereck E, Twist CJ, Wang M. Measuring pediatric hematology-oncology fellows’ skills in humanism and professionalism: A novel assessment instrument. Pediatr Blood Cancer 2017 May 64(5): doi10.1002/pbc.26316.

Berry JL, Kogachi K, Aziz HA, McGovern K, Zolfaghri, Murphree AL, Jubran R, Kim JW. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatr Blood Cancer 2017, Apr 64(4) doi:10.1002/pbc.2670.

Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Long term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017 Jun24 doi: 10.1002/pbc.26696 [epub ahead of print]

Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Not all seeds are created equal: Seed classification is predictive of outcomes in retinoblastoma. Ophthalmology 2017 Jun24 [epub ahead of print].

 

Research Interests: 

Clinical research include retinoblastoma and histiocytic disorders of childhood.

4650 Sunset Blvd.
#54
Los Angeles, CA 92064
Phone: 323-361-4624Office